A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Autor: Li, John Y., Perry, Samuel R., Muniz-Medina, Vanessa, Wang, Xinzhong, Wetzel, Leslie K., Rebelatto, Marlon C., Hinrichs, Mary Jane Masson, Bezabeh, Binyam Z., Fleming, Ryan L., Dimasi, Nazzareno, Feng, Hui, Toader, Dorin, Yuan, Andy Q., Xu, Lan, Lin, Jia, Gao, Changshou, Wu, Herren, Dixit, Rakesh, Osbourn, Jane K., Coats, Steven R.
Zdroj: In Cancer Cell 11 January 2016 29(1):117-129
Databáze: ScienceDirect